Crossing Biological Barriers by Engineered Nanoparticles

Jia, Jianbo; Wang, Zengjin; Yue, Tongtao; Su, Gaoxing; Teng, Chuanfeng; Yan, Bing

doi:10.1021/acs.chemrestox.9b00483

Cited by 52 publications

(28 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Maternal intrauterine inflammation significantly increased the maternal-fetal transfer of Au NPs (3 nm and 13 nm) [120]. Finally, secondary modifications of NPs by biofluid components, such as the formation of protein corona, affected the placental transfer of NPs [124,131].…”

Section: Maternal-fetal Np Transfermentioning

confidence: 99%

“…Previous studies demonstrated that CB NPs, CNTs, PS NPs, Si O 2 NPs [118], TiO 2 NPs [118], ZnO NPs [11,48], ZrO 2 NPs [18,119], CeO 2 NPs, Au NPs [120][121][122], Ag NPs, and quantum dots (QDs) [15,123] could cross the placental barrier and induce fetotoxicity. Properties of NPs, maternal conditions, exposure schedule, and modification of NPs by biofluid components affected the placental transfer efficiency of NPs [124,125].…”

Section: Maternal-fetal Np Transfermentioning

confidence: 99%

See 1 more Smart Citation

Fetotoxicity of Nanoparticles: Causes and Mechanisms

et al. 2021

Self Cite

View full text Add to dashboard Cite

The application of nanoparticles in consumer products and nanomedicines has increased dramatically in the last decade. Concerns for the nano-safety of susceptible populations are growing. Due to the small size, nanoparticles have the potential to cross the placental barrier and cause toxicity in the fetus. This review aims to identify factors associated with nanoparticle-induced fetotoxicity and the mechanisms involved, providing a better understanding of nanotoxicity at the maternal–fetal interface. The contribution of the physicochemical properties of nanoparticles (NPs), maternal physiological, and pathological conditions to the fetotoxicity is highlighted. The underlying molecular mechanisms, including oxidative stress, DNA damage, apoptosis, and autophagy are summarized. Finally, perspectives and challenges related to nanoparticle-induced fetotoxicity are also discussed.

show abstract

Section: Maternal-fetal Np Transfermentioning

confidence: 99%

Section: Maternal-fetal Np Transfermentioning

confidence: 99%

Fetotoxicity of Nanoparticles: Causes and Mechanisms

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…35 The increase in circulation time has two effects: on the one hand it allows for higher accumulation of the nano-carriers on the site of the diseased tissue, while at the same time it increases the likelihood of crossing biological barriers and accumulating vital organs, thus increasing non-selective toxicity. 36…”

Section: A Nanotoxicitymentioning

confidence: 99%

Nano-drug Clinical Trials: Informed Consent and Risk Management Through Blockchain

Haik¹,

Bantekas²

2021

tlp

View full text Add to dashboard Cite

Drug bearing nano-shells that can be utilized for targeted drug delivery have been shown to enhance the therapeutic index by increasing the dug concentration in diseased tissue and reducing the toxicity in normal tissue. The controllability of the drug bearing shell size provides predictability measure for the amount of drug payload per shell which improves the administration of the therapeutic dose. The FDA approved different formulations for clinical use in metastatic and recurrent breast cancer, among other diseases. At the moment, some of these formulations are the subject of international clinical trials. Informed consent is legally mandated in administering drug bearing nano-shells. The risks of the new formulations, as with all new technologies, are not well known and are continue to be a subject of intensive research, thus exacerbating the existing informed consent legal issues, thus exacerbating the existing informed consent legal issues. This short essay focuses on proposing a framework to mitigate liabilities administering a new formulation on nano-enabled drug carriers particularly when uncertainties of the benefits and damages are not fully known.

show abstract

“…Enhanced permeability and retention of nanoparticles can account for >20% increase in nanoparticle accumulation compared to healthy organs [ 94 ]. On the other hand, complications of human diseases, such as fibrosis and aberrant circulation, can markedly reduce blood flow and the access of nanoparticles to organs [ 95 ].…”

Section: Extracellular Vesicles (Ev) As Drug Delivery Vehiclesmentioning

confidence: 99%

Gene Editing by Extracellular Vesicles

Kostyushev

Kostyusheva

Brezgin

et al. 2020

IJMS

View full text Add to dashboard Cite

CRISPR/Cas technologies have advanced dramatically in recent years. Many different systems with new properties have been characterized and a plethora of hybrid CRISPR/Cas systems able to modify the epigenome, regulate transcription, and correct mutations in DNA and RNA have been devised. However, practical application of CRISPR/Cas systems is severely limited by the lack of effective delivery tools. In this review, recent advances in developing vehicles for the delivery of CRISPR/Cas in the form of ribonucleoprotein complexes are outlined. Most importantly, we emphasize the use of extracellular vesicles (EVs) for CRISPR/Cas delivery and describe their unique properties: biocompatibility, safety, capacity for rational design, and ability to cross biological barriers. Available molecular tools that enable loading of desired protein and/or RNA cargo into the vesicles in a controllable manner and shape the surface of EVs for targeted delivery into specific tissues (e.g., using targeting ligands, peptides, or nanobodies) are discussed. Opportunities for both endogenous (intracellular production of CRISPR/Cas) and exogenous (post-production) loading of EVs are presented.

show abstract

Crossing Biological Barriers by Engineered Nanoparticles

Cited by 52 publications

References 64 publications

Fetotoxicity of Nanoparticles: Causes and Mechanisms

Fetotoxicity of Nanoparticles: Causes and Mechanisms

Nano-drug Clinical Trials: Informed Consent and Risk Management Through Blockchain

Gene Editing by Extracellular Vesicles

Contact Info

Product

Resources

About